Latest Ivabradine Stories
Corlanor is the First New Chronic Heart Failure Medicine Approved by the FDA in Nearly a Decade THOUSAND OAKS, Calif., April 15, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that
Data Evaluating the Effect of Repatha(TM)(Evolocumab) on LDL-C and Cardiovascular Events to be Featured in Late-Breaking Session THOUSAND OAKS, Calif., March 2, 2015 /PRNewswire/ -- Amgen (NASDAQ:AMGN)
The Acute Heart Failure Market Will Also Experience Substantial Growth Following the Launch of Two Novel Vasodilator Therapies, According to Findings from Decision Resources Group BURLINGTON,
Analysis From SHIFT Study Shows Ivabradine Reduced Cardiovascular Death or Hospitalization for Worsening Heart Failure Independent of Baseline Blood Pressure With Similar Safety Profile Across Groups THOUSAND
THOUSAND OAKS, Calif., Aug. 27, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the U.S.
Considerable Opportunity Exists for Therapies Offering Reductions in Mortality and Hospitalization Rates, According to Findings from Decision Resources Group BURLINGTON, Mass., April 14, 2014
As guest speaker at the European Society of Cardiology's Congress currently under way in Paris, Dr. Jean-Claude Tardif, Director of the Montreal Heart Institute's Research Centre and professor of medicine at the Université de Montréal, today presented the results of an analysis demonstrating that ivabradine, a medication used to reduce heart rate, also reduces heart volume (left ventricle) among patients with cardiac insufficiency.
The findings of a Montreal Heart Institute (MHI) study published in the scientific journal Cardiology suggest that ivabradine, a heart rate reduction medication, is also effective in reducing the risk of diastolic heart failure (left ventricular insufficiency) and cardiac fibrosis.
- Emitting flashes of light; glittering.